Moderna, Inc. (NASDAQ:MRNA – Get Rating) – Analysts at SVB Leerink lowered their Q1 2022 EPS estimates for shares of Moderna in a research report issued to clients and investors on Tuesday, April 26th. SVB Leerink analyst M. Foroohar now forecasts that the company will post earnings of $2.97 per share for the quarter, down from their prior estimate of $7.70. SVB Leerink currently has a “Underperform” rating and a $80.00 price target on the stock. SVB Leerink also issued estimates for Moderna’s Q2 2022 earnings at $6.61 EPS and Q4 2022 earnings at $8.56 EPS.
Several other research analysts also recently issued reports on MRNA. Argus cut their price objective on Moderna from $420.00 to $350.00 in a research report on Thursday, January 6th. Bank of America upgraded Moderna from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $135.00 to $180.00 in a research report on Friday, January 21st. Morgan Stanley lifted their price objective on Moderna from $205.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. Barclays cut their price objective on Moderna from $404.00 to $210.00 in a research report on Friday, February 25th. Finally, Redburn Partners upgraded Moderna from a “sell” rating to a “neutral” rating in a research report on Tuesday, February 1st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $242.71.
Moderna (NASDAQ:MRNA – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported $11.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $9.83 by $1.46. The business had revenue of $7.21 billion for the quarter, compared to analyst estimates of $6.73 billion. Moderna had a return on equity of 140.21% and a net margin of 66.06%. The company’s quarterly revenue was up 1163.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.69) EPS.
Several hedge funds have recently bought and sold shares of the company. Field & Main Bank acquired a new stake in Moderna during the 4th quarter valued at approximately $25,000. Confluence Wealth Services Inc. acquired a new stake in Moderna during the 4th quarter valued at approximately $25,000. Standard Family Office LLC acquired a new stake in Moderna during the 4th quarter valued at approximately $25,000. Reilly Financial Advisors LLC acquired a new position in shares of Moderna in the 4th quarter worth approximately $26,000. Finally, Gradient Investments LLC grew its position in shares of Moderna by 2,000.0% in the 4th quarter. Gradient Investments LLC now owns 105 shares of the company’s stock worth $27,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 60.11% of the company’s stock.
In other news, CEO Stephane Bancel sold 9,000 shares of the stock in a transaction dated Wednesday, April 20th. The stock was sold at an average price of $150.59, for a total value of $1,355,310.00. Following the completion of the sale, the chief executive officer now owns 5,434,535 shares in the company, valued at $818,386,625.65. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, President Stephen Hoge sold 10,000 shares of the stock in a transaction dated Wednesday, February 2nd. The shares were sold at an average price of $170.89, for a total value of $1,708,900.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 199,054 shares of company stock worth $32,244,814. Company insiders own 17.30% of the company’s stock.
Moderna Company Profile (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- Automatic Data Processing Is Ready To Scale New Heights
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.